Share Name Share Symbol Market Type Share ISIN Share Description
Acacia Pharma Group Plc LSE:0PNT London Ordinary Share GB00BYWF9Y76 ACACIA PHARM ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 0.00 -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0

Acacia Pharma Group plc Notice Of Results

23/09/2021 12:00pm

UK Regulatory (RNS & others)

Acacia Pharma (LSE:0PNT)
Historical Stock Chart

From Jul 2021 to Jan 2022

Click Here for more Acacia Pharma Charts.

Acacia Pharma to Report its Interim Results for the Six Months ended 30 June 2021 on 30 September 2021

Conference Call to be held on 30 September at 14.00 CEST/08.00 EST

Cambridge, UK and Indianapolis, US -- 23 September 2021, 13:00 CEST: Acacia Pharma Group plc ("Acacia Pharma" or the "Company") (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces that it will report its interim results for the half year ended 30 June 2021 at 07.00 CEST on Thursday 30 September.

A presentation by Acacia Pharma's senior management team will be webcast live the same day at 14.00 CEST (08.00 EST) and will include an update on progress with the US commercialization of Barhemsys(R) and Byfavo(R).

The webcast can be accessed from https://www.globenewswire.com/Tracker?data=wcTgQzNLZFWNyh1CmqrZbGA1iEFwujhF8CgZNJTPU6HignJkrnR12IiOLHII-7u2TnRCwG3YbKgoVA5DTX-pTG2bYdWYp4UzxekisMolSQ4= www.acaciapharma.com and a recording will be available after the event.

The interim results report will be available at https://www.globenewswire.com/Tracker?data=wcTgQzNLZFWNyh1CmqrZbGA1iEFwujhF8CgZNJTPU6EumMwAf_L7UtRt13ArTiLECbz3OvFElzQ1aKcDxO4-Mu4CkTkD1IdExJPNCmO5GzA= www.acaciapharma.com in the Investors section from 07.00 CEST on 30 September and slides for the conference call will be made available shortly before the start.

As previously announced, Acacia will also hold a KOL webinar later today at 18.00 CEST/12.00 EDT. Advanced registration is required, and details can be found on our website under the Media/Events section.



Acacia Pharma Group plc                          International Media 
 Mike Bolinder, CEO                               Mark Swallow, Frazer Hall, David 
 Gary Gemignani, CFO                              Dible 
 +44 1223 919760 / +1 317 505 1280                MEDiSTRAVA Consulting 
 mailto:IR@acaciapharma.com IR@acaciapharma.com   +44 20 7638 9571 
-----------------------------------------------  ------------------------------------ 
US Investors                                     Media in Belgium and the Netherlands 
 LifeSci Advisors                                 Chris Van Raemdonck 
 Irina Koffler                                    +32 499 58 55 31 
 +1 917-734-7387                                  mailto:chrisvanraemdonck@telenet.be 
 mailto:ikoffler@lifesciadvisors.com              chrisvanraemdonck@telenet.be 
-----------------------------------------------  ------------------------------------ 

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Acacia Pharma's first product, Barhemsys(R) (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV).

Byfavo(R) (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. Byfavo is in-licensed from Paion UK Limited for the US market.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centered in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

https://www.globenewswire.com/Tracker?data=wcTgQzNLZFWNyh1CmqrZbGA1iEFwujhF8CgZNJTPU6EBPszGynnNCDQPAR2_HxJG-3-ByKSmmmI0IA5m2oHeKDQ-TEMmgyi1XbNJuxzzEio= www.acaciapharma.com


(END) Dow Jones Newswires

September 23, 2021 07:00 ET (11:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Acacia Pharma Chart

1 Year Acacia Pharma Chart

1 Month Acacia Pharma Chart

1 Month Acacia Pharma Chart
ADVFN Advertorial
Your Recent History
Acacia Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220127 06:42:45